{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"11.8","upperLimit":"29.9","value":"18"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"}],"units":"Participants"}],"description":"Overall Survival is defined as the time from registration to death. The distribution of survival will be estimated using the method of Kaplan-MeierEstimated using Kaplan-Meier methodology.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive Akt inhibitor MK2206 PO once weekly for 4 weeks. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nAkt Inhibitor MK2206: 150 mg given PO","id":"OG000","title":"Treatment (Akt Inhibitor MK2206)"}],"paramType":"MEDIAN","populationDescription":"Two patients were not eligible for this endpoint.","reportingStatus":"POSTED","timeFrame":"Time of study entry to death due to any cause, assessed up to 3 years from registration","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}